• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Cougar Biotechnology Announces CB7630 Phase I Data to Be Presented at National Cancer Research Institute Conference

Posted on: Wednesday, 27 September 2006, 15:01 CDT

Cougar Biotechnology, Inc., a publicly held biotechnology company, today announced that Phase I data on the Company's prostate cancer drug CB7630 (abiraterone acetate) will be presented at National Cancer Research Institute (NCRI) Cancer Conference that will take place October 8-11, 2006 in Birmingham, UK. The presentation, which will take place during the plenary session on October 8th, is entitled "Inhibition of androgen synthesis by an oral, irreversible, inhibitor of CYP450c17 appears safe and results in a high, durable, response rate in castration refractory prostate cancer (CRPC) patients" and will be presented by Dr. Johann S. deBono, MSc, PhD, MD, FRCP from the Institute of Cancer Research and Royal Marsden Hospital in Sutton, UK. Further information about the NCRI conference and the presentation can be found at: http://www.ncri.org.uk/ncriconference/programme/01day/Prog_DayOne.htm.

"The NCRI conference is the largest annual conference on cancer in the United Kingdom. We are pleased to be able to present this data at such a well respected international conference," said Dr. Arie Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology. Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "This will represent the first public presentation of data for CB7630 as a second line hormonal agent for patients with advanced prostate cancer who have failed treatment with first line hormonal therapy. As this continues to be a patient group that is underserved by current treatments, we look forward to the continued development of CB7630 in this area."

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based publicly held biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme which is currently being tested in a Phase I clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause Cougar's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates,""expects,""plans,""believes,""intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Cougar's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Cougar's product candidates, the risk that the results of clinical trials may not support Cougar's claims, Cougar's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 7, 2006. Cougar assumes no obligation to update these statements, except as required by law.

Source: Business Wire

More News in this Category